GARDASIL(R) Is First Cervical Cancer Vaccine To Receive WHO Pre-qualification
GARDASIL(R) Is First Cervical Cancer Vaccine To Receive WHO Pre-qualification
GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], Merck's cervical cancer vaccine, has been awarded World Health Organization (WHO) pre-qualification. GARDASIL is the first cervical cancer vaccine to receive WHO pre-qualification.
What next?
Posting Komentar